PhRMA, BIO Mum On Trump’s Tariffs

While pressing the US trade representative for stronger IP protection, groups representing the brand biopharma sector remain silent on the Trump administration’s plan to hit China with 25% tariffs.

US/China tariff war could affect pharmaceuticals

More from Manufacturing

More from Compliance